MedTrace Logo

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

NCT06193902 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-09-03

No results posted yet for this study

Summary

This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.

Conditions

  • Tumor, Solid

Interventions

BIOLOGICAL

LEU011

Immunotherapy

Sponsors & Collaborators

  • Leucid Bio

    lead INDUSTRY

Principal Investigators

  • John Maher · Leucid Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06193902 on ClinicalTrials.gov